Personalized therapy for metastatic melanoma: Could timing be everything?

Roxana S. Dronca; Alexey A. Leontovich; Wendy K. Nevala; Svetomir N. Markovic

doi:10.2217/fon.12.126

Personalized therapy for metastatic melanoma: Could timing be everything?

Roxana S. Dronca, Alexey A. Leontovich, Wendy K. Nevala, Svetomir N. Markovic

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

There is ample evidence that immune-related processes in humans are under temporal regulation. The circadian variation of humoral and cellular immunity is well documented and appears to be hormonally modulated via the hypothalamic-pituitary-adrenal axis. In advanced melanoma, it has recently been demonstrated that systemic immunity is repolarized toward a global state of chronic inflammation (Th2 dominance) and appears to be governed by infradian biorhythms of cytokines and immune cell subsets, which extend beyond the 24-h circadian variability reported in healthy volunteers. It is suggested that synchronizing administration of lymphodepleting chemotherapy (temozolomide) with these endogenous (individualized) immune dynamics (biorhythms) in patients with advanced/metastatic melanoma improves clinical outcomes compared with temozolomide used in a conventional 'random delivery' fashion.

Original language	English (US)
Pages (from-to)	1401-1406
Number of pages	6
Journal	Future Oncology
Volume	8
Issue number	11
DOIs	https://doi.org/10.2217/fon.12.126
State	Published - Nov 2012

Keywords

biorhythms
cancer
chemotherapy
cytokine
immunity
infradian
melanoma

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon.12.126

Fingerprint Dive into the research topics of 'Personalized therapy for metastatic melanoma: Could timing be everything?'. Together they form a unique fingerprint.

Cite this

@article{5f88685bc72c46d186295d625f7122e5,

title = "Personalized therapy for metastatic melanoma: Could timing be everything?",

abstract = "There is ample evidence that immune-related processes in humans are under temporal regulation. The circadian variation of humoral and cellular immunity is well documented and appears to be hormonally modulated via the hypothalamic-pituitary-adrenal axis. In advanced melanoma, it has recently been demonstrated that systemic immunity is repolarized toward a global state of chronic inflammation (Th2 dominance) and appears to be governed by infradian biorhythms of cytokines and immune cell subsets, which extend beyond the 24-h circadian variability reported in healthy volunteers. It is suggested that synchronizing administration of lymphodepleting chemotherapy (temozolomide) with these endogenous (individualized) immune dynamics (biorhythms) in patients with advanced/metastatic melanoma improves clinical outcomes compared with temozolomide used in a conventional 'random delivery' fashion.",

keywords = "biorhythms, cancer, chemotherapy, cytokine, immunity, infradian, melanoma",

author = "Dronca, {Roxana S.} and Leontovich, {Alexey A.} and Nevala, {Wendy K.} and Markovic, {Svetomir N.}",

year = "2012",

month = nov,

doi = "10.2217/fon.12.126",

language = "English (US)",

volume = "8",

pages = "1401--1406",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "11",

}

TY - JOUR

T1 - Personalized therapy for metastatic melanoma

T2 - Could timing be everything?

AU - Dronca, Roxana S.

AU - Leontovich, Alexey A.

AU - Nevala, Wendy K.

AU - Markovic, Svetomir N.

PY - 2012/11

Y1 - 2012/11

N2 - There is ample evidence that immune-related processes in humans are under temporal regulation. The circadian variation of humoral and cellular immunity is well documented and appears to be hormonally modulated via the hypothalamic-pituitary-adrenal axis. In advanced melanoma, it has recently been demonstrated that systemic immunity is repolarized toward a global state of chronic inflammation (Th2 dominance) and appears to be governed by infradian biorhythms of cytokines and immune cell subsets, which extend beyond the 24-h circadian variability reported in healthy volunteers. It is suggested that synchronizing administration of lymphodepleting chemotherapy (temozolomide) with these endogenous (individualized) immune dynamics (biorhythms) in patients with advanced/metastatic melanoma improves clinical outcomes compared with temozolomide used in a conventional 'random delivery' fashion.

AB - There is ample evidence that immune-related processes in humans are under temporal regulation. The circadian variation of humoral and cellular immunity is well documented and appears to be hormonally modulated via the hypothalamic-pituitary-adrenal axis. In advanced melanoma, it has recently been demonstrated that systemic immunity is repolarized toward a global state of chronic inflammation (Th2 dominance) and appears to be governed by infradian biorhythms of cytokines and immune cell subsets, which extend beyond the 24-h circadian variability reported in healthy volunteers. It is suggested that synchronizing administration of lymphodepleting chemotherapy (temozolomide) with these endogenous (individualized) immune dynamics (biorhythms) in patients with advanced/metastatic melanoma improves clinical outcomes compared with temozolomide used in a conventional 'random delivery' fashion.

KW - biorhythms

KW - cancer

KW - chemotherapy

KW - cytokine

KW - immunity

KW - infradian

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=84869170306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869170306&partnerID=8YFLogxK

U2 - 10.2217/fon.12.126

DO - 10.2217/fon.12.126

M3 - Article

C2 - 23148614

AN - SCOPUS:84869170306

VL - 8

SP - 1401

EP - 1406

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 11

ER -